#USA #New York #Rosen Law Firm #LifeMD #LFMD

LifeMD Securities Fraud Lawsuit: Deadline for Action Approaches

Investors of LifeMD, Inc. (NASDAQ: LFMD) should take notice: The Rosen Law Firm, a prominent global investor advocacy group, has issued a reminder concerning a significant deadline pertaining to a securities fraud lawsuit against LifeMD. This class action lawsuit involves the purchase of LifeMD securities that occurred between May 7, 2025, and August 5, 2025. The deadline for potential lead plaintiffs to step forward is October 27, 2025.

Important Information for Investors

If you acquired LifeMD securities during this specific period, you may be eligible for compensation if you join the class action lawsuit initiated by The Rosen Law Firm. Notably, this can be done without incurring any out-of-pocket fees or costs, as the firm operates under a contingency fee arrangement. In the event of a successful outcome, legal costs would be deducted from the settlement amount.

To take action and join the LifeMD class action, you must either visit this link or contact Phillip Kim, Esq. at 866-767-3653. It’s essential to remember that a class has not yet been certified, meaning that until such certification is granted, investors are not represented by any legal counsel unless they independently retain one.

Why You Should Consider Joining

The Rosen Law Firm stresses the significance of choosing a competent legal representative with a history of success in cases of this nature. In many instances, other firms may lack the experience or resources to adequately pursue justice for investors. Many firms merely act as intermediaries, forwarding cases to actual litigators, which diminishes the likelihood of achieving favorable outcomes.

The Rosen Law Firm specializes in representing investors in class actions and shareholder derivative litigation. They have a proven track record, having secured substantial settlements. For instance, the Rosen Law Firm achieved the largest securities class action settlement against a Chinese company at that time and has consistently been ranked among the top firms for securities class action settlements.

Allegations of Misconduct

The lawsuit posits that during the class period, LifeMD executives made materially false or misleading statements regarding the company’s competitive standing and future projections. Specifically, it is alleged that:

• - The defendants significantly exaggerated LifeMD’s competitive position in the market.
• - They recklessly issued overly optimistic financial forecasts for 2025 without accounting for increased customer acquisition costs in the RexMD segment and the costs related to new drug sales aimed at treating obesity.
• - As a result, these misleading statements misrepresented the company's business and operational health, causing financial damage to investors when the actual circumstances came to light.

How to Move Forward

Investors interested in participating in this action must act before the looming deadline on October 27, 2025. Engaging with the lawsuit allows shareholders to potentially reclaim losses without facing any upfront costs. Furthermore, an interested investor can choose to remain an absent class member, opting not to serve as a lead plaintiff while still maintaining rights to any potential recovery.

For ongoing updates and more information about the lawsuit’s development, investors are encouraged to stay connected with The Rosen Law Firm through their LinkedIn or Twitter accounts.

In conclusion, if you are a LifeMD investor who fits within the described class, this is a pivotal moment to consider your options and potentially protect your investments before the deadline. Take the necessary steps to align with a strong legal team that will advocate on your behalf in this significant securities class action.